Open company graph database — free web & API
Login

Sawai Group Holdings Co., Ltd.

サワイグループホールディングス株式会社SAWAI GROUP HOLDINGS Co., Ltd.Alias
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
3,630
Related companies
5
§01

Basic information

BASIC
Head office
5-2-30 Miyahara, Yodogawa-ku, Osaka City
Chief executive
Mitsuhiro Sawai
Capital
10,000,000,000  (100 100 million)
Employees (non-consolidated)
98 people
Employees (consolidated)
3,630 people
Start date
2021-04-01
End date
§02

Websites

1 DOMAINS
§03

Business

1
A holding company responsible for group management and related operations
§04

Related companies

5 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
FrontAct Corporation
Group Customer
Trust PharmaTech Co., Ltd.
Group Customer
Medisa New Drug Inc.
Group Customer
Kaken Seiyaku Co., Ltd.
Group Customer
Sawai Pharmaceutical Co., Ltd.
Group Customer
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

139 EVENTS

Founded by Kohei Sawai and Noyo (pharmacist) in Asahi Ward, Osaka City, as the predecessor of Sawai Pharmaceutical Co., Ltd., Sawai Pharmacy.Sources

Established Kaken Seiyaku Co., Ltd. in Kudan, Tokyo, with a capital of 190,000 yen.Sources

Established Sawai Pharmaceutical Co., Ltd. (now Sawai Pharmaceutical Co., Ltd.) in Asahi Ward, Osaka City, with a capital of 195,000 yen.Sources

Sources

Sources

Opened Tokyo Branch (now Tokyo First Branch).Sources

Sources

Sources

Automated the production line at the head office factory (at that time).Sources

Sources

Established Sapporo Sales Office (now Sapporo Branch), Tohoku Sales Office (now Sendai Branch), Nagoya Sales Office (now Nagoya Branch), and Fukuoka Sales Office (now Fukuoka Branch).Sources

Obtained patent for garlic extract manufacturing method and launched vitamin B1 preparations.Sources

Sources

Sources

Shifted from a manufacturer of over-the-counter drugs to a manufacturer of prescription drugs.Sources

Completed Osaka Second Factory (at that time) in Asahi Ward, Osaka City.Sources

Established a shipping center in Miyakojima Ward, Osaka City, to improve logistics from manufacturing to sales.Sources

Sources

Completed the head office building (at that time) in Asahi Ward, Osaka City, and relocated the head office functions.Sources

Jiro Sawai became President and CEO, and Hiroyuki Sawai was appointed Senior Managing Director.Sources

Changed the company name to Sawai Pharmaceutical Co., Ltd.Sources

Established Hiroshima Sales Office (now Hiroshima Branch).Sources

Sources

Completed Kyushu Factory in Iizuka City, Fukuoka Prefecture.Sources

Established Yaso Factory in Ishioka City, Ibaraki Prefecture.Sources

Sources

Sources

Completed the second phase of Kyushu Factory (manufacturing equipment for general formulations and syrup formulations).Sources

Established Osaka Research Institute (at that time) in Asahi Ward, Osaka City.Sources

Established Medisa New Drug Co., Ltd. (now a consolidated subsidiary) in Chuo Ward, Tokyo.Sources

Completion of the third phase construction of the Kyushu Factory (injectable drug manufacturing equipment).Sources

Completion of the Kyushu Factory (currently Sawai Pharmaceutical Co., Ltd. Second Kyushu Factory) in Kaho District, Fukuoka Prefecture (now Iizuka City).Sources

Sources

Sources

Jiro Sawai appointed as Chairman of the Board, Hiroyuki Sawai appointed as President and CEO.Sources

Completion of the fourth phase construction of the Kyushu Factory (expansion of injectable drug manufacturing facilities, etc.).Sources

Established a research and development center in Asahi-ku, Osaka City, to expand the R&D department.Sources

Opened an Osaka branch.Sources

Sources

Separated and established an independent shipping center, and established Active Work Co., Ltd., a wholly owned subsidiary.Sources

Made Medisa New Drug Co., Ltd. a subsidiary.Sources

Completion of the second phase construction of the Kyushu Factory (packaging equipment) at the current Sawai Pharmaceutical Co., Ltd. Second Kyushu Factory.Sources

Completed the Mita Factory in Sanda City, Hyogo Prefecture.Sources

Established a formulation research center (at that time) in Asahi-ku, Osaka City, to enhance formulation research.Sources

Sources

Listed on the over-the-counter market of the Japan Securities Dealers Association.Sources

Completion of the third phase construction of the Kyushu Factory (product warehouse, quality control analysis room, cafeteria, etc.) at the current Sawai Pharmaceutical Co., Ltd. Second Kyushu Factory.Sources

Sources

Started publishing newspaper advertisements to promote awareness of generic medicines.Sources

Completion of the fourth and fifth phase constructions of the Kyushu Factory (general formulation manufacturing equipment, automatic warehouse expansion).Sources

Sources

Sources

Sources

Expanded injectable drug manufacturing facilities at the Kyushu Factory.Sources

Listed on the Second Section of the Tokyo Stock Exchange.Sources

Completion of the fifth phase construction of the Kyushu Factory (oral sustained-release formulations, etc., manufacturing equipment, packaging equipment).Sources

Designated on the First Section of the Tokyo Stock Exchange.Sources

Sources

Established a new visual identity.Sources

Started broadcasting TV commercials nationwide.Sources

Merged with the consolidated subsidiary, Active Work Inc.Sources

Sources

Sources

Sources

Completion of the second phase of the Sanda Factory (expansion of general formulation manufacturing equipment and special formulation equipment).Sources

Acquired the Mobara Factory of Nippon Sieiling Co., Ltd. (now Bayer Yakuhin Ltd.) in Mobara City, Chiba Prefecture, and operated as the Kanto Factory.Sources

Sources

Sumitomo Corporation Group invested in Medisa New Drug.Sources

Relocated headquarters to Asahi-ku, Osaka City.Sources

Completed new headquarters and research building in Yodogawa-ku, Osaka City.Sources

Made Kaken Seiyaku Co., Ltd. a subsidiary through share acquisition.Sources

Established a syringe building at the Kanto Factory.Sources

Formulated corporate philosophy and code of conduct.Sources

Completion of the 6th phase of the Kyushu Factory (current Sawai Pharmaceutical Co., Ltd. Second Kyushu Factory) expansion including oral solid dosage production equipment.Sources

Relocated headquarters to Yodogawa-ku, Osaka City.Sources

Hiroyuki Sawai was appointed Chairman and Mitsuo Sawai was appointed President.Sources

Sources

Completion of the third phase of the Sanda Factory (expansion of general formulation manufacturing equipment).Sources

Established Saitama Branch (now Tokyo Second Branch).Sources

Established Formulation Research Center (later renamed Formulation Technology Center).Sources

Sources

Fully acquired Medisa New Drug.Sources

Sources

The anti-allergy drug "Cetirizine Hydrochloride OD Tablets 'Sawai'" received the Best Generic Drug Award from the Japan Generic Medicines Association.Sources

Sources

Sources

Through company split, absorbed the production business of Medisa New Drug, and succeeded the Kyushu Factory as Sawai Pharmaceutical's Second Kyushu Factory.Sources

Sources

Established a formulation factory at the Kanto Factory.Sources

Sleep inducer "Zolpidem Tartrate OD Tablets "Sawai"" received the Generic Drug Encouragement Award.Sources

Sources

Antiplatelet drug "Cilostazol OD Tablets "Sawai"" received the Asahi Kasei Drug Development Technology Award.Sources

Sources

Sources

Sources

Inherit the Kashima Factory (Kamisunashi, Ibaraki Prefecture) and start operation.Sources

Established a new development center in Suita City, Osaka Prefecture.Sources

Completed the Mita West Factory in Sanda City, Hyogo Prefecture.Sources

Sources

Pitabastatin tablets approved by the FDA.Sources

Acquired Upsher-Smith Laboratories, LLC through Sawai America INC.Sources

Sources

Sources

Celebrating the 90th anniversary of founding.Sources

The packaging of Minodronate 50mg "Sawai" for osteoporosis treatment received the WorldStar Awards.Sources

Sources

Sources

Signed a joint development and licensing agreement with NewGen Pharma for ALS treatment drugs.Sources

Mitsuhiro Sawai appointed as Chairman of the Board, Kenzo Sawai as President and CEO.Sources

Agreed on capital and business alliance with SumoMed Corporation.Sources

Sources

Sources

Sources

Sources

Signed an exclusive development and sales agreement in Japan with NeuroReef for digital medical devices for migraines and depression.Sources

Established Sawai Group Holdings Co., Ltd.Sources

Mitsuhiro Sawai appointed as Chairman of the Board and President, Kenzo Sawai as Vice Chairman, and Kazuhiko Sueyoshi as President and CEO.Sources

Launched the Personal Health Record (PHR) management app "SaluDi".Sources

Established Trust PharmaTech Co., Ltd.Sources

Sources

Sources

Sources

Sources

Signed a licensing agreement with CureApp Co., Ltd. for DTx development and sales in the NASH field.Sources

Built a new injection building at the Kyushu factory.Sources

Sources

Mitsuhiro Sawai appointed as Chairman and President.Sources

Kimura Motohiko appointed as President and CEO.Sources

Obtained approval for manufacturing and sales of non-invasive neuromodulation devices.Sources

Sources

Sources

Sources

Sold Upsher-Smith Laboratories, LLC.Sources

Established a new solid dosage building at the Second Kyushu Factory.Sources

Entered into a licensing agreement with CureApp Inc. for the sale of alcohol reduction treatment support app.Sources

Sources

Sawai Group Holdings acquires FrontAct Inc.Sources

Sources

Sources

§07

News

9 ARTICLES

Sawai Group Achieves 100% Childcare Leave Take-up Rate Ahead of ScheduleSources

Sawai Group Holdings achieved a 100% childcare leave take-up rate among male employees ahead of schedule in fiscal 2025, reaching 108%. Through continuous awareness reform and strengthening support systems, the goal was realized early.

Sawai Group Holdings Donates 10 Million Yen in Relief FundsSources

Sawai Group Holdings has donated 10 million yen as relief funds through the Japanese Red Cross Society to support victims and aid recovery from the Kumamoto Earthquake in Reiwa 8. They express their sympathy to the victims and pray for reconstruction.

Sawai Group Holdings, Social Bond Conditions DecidedSources

Sawai Group Holdings has decided the conditions for issuing a domestic public offering social bond on July 24, 2026. The issuance amount is 10 billion yen, with a 10-year redemption period and an interest rate of 3.441%. The funds will be used for investments in subsidiaries and for capital investment in a factory in Fukui Prefecture.

Sawai Group Holdings Adoption Forest Signing Ceremony ParticipationSources

Sawai Group Holdings participated in the signing ceremony in support of the Adopt Forest system in Osaka Prefecture, promoting activities for the conservation of forests and farmland.

Sawai Group Holdings Personnel Changes AnnouncementSources

Sawai Group Holdings will implement personnel changes, transferring Mr. Yoshihiro Nishihara to the position of Director and Group Finance Department Manager, effective July 1, 2026.

Sawai Group Announces Subsidiary MergerSources

Sawai Group Holdings has decided to absorb and merge its consolidated subsidiary, Trust Pharmatech, into Sawai Pharmaceutical on April 1, 2027.

Sawai Group Holdings Certified as a Health Management Excellence Corporation 2026Sources

Sawai Group Holdings has been selected as a Health Management Excellence Corporation 2026 and is working on employee health management and improving the workplace environment.

Sawai Group Holdings Personnel Changes AnnouncementSources

Sawai Group Holdings will implement personnel changes for multiple executives effective April 1, 2026.

Sawai Group Holdings Notice of Discontinuation of Sending Greetings for Director ReorganizationSources

Sawai Group Holdings announced that, in order to promote environmental considerations and digitalization, they will cease sending greetings for director reorganization and will provide information about the future director system on their website.

§08

Public records

GOV
National Tax Agency basic information8120001236516
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
サワイグループホールディングス株式会社
Trade name (kana)
サワイグループホールディングス
Name in English
Corporation type
301
Address
〒532-0003 大阪府大阪市淀川区宮原5丁目2番30号
Postal code
5320003
Prefecture code
27
City code
123
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2021-04-12
Update date
2021-04-12
Change date
2021-04-12
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
0
Trade name image ID
Address image ID
Sequence number
4372780
METI gBizINFO8120001236516
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
8120001236516
Trade name
サワイグループホールディングス株式会社
Trade name (kana)
サワイグループホールディングス
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
大阪府大阪市淀川区宮原5丁目2番30号
Postal code
5320003
Prefecture
大阪府
Prefecture code
27
City or district
大阪市淀川区
City code
123
Street address
宮原5丁目2番30号
Organisation type
301
Processing type
01
Correction type
0
Status
Representative
代表取締役社長 グループCEO兼グループCOO 澤井 光郎
Capital
10079000000
Employees
110
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2021-04-12
Key information
8120001236516
§09

Sources & updates

SOURCES
↑